At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Protocol 2: Elucidation of Mechanisms Responsible for the Increase in EGP Following SGLT2 Inhibition: Decrease in Plasma Glucose Conc or Change in Islet Hormone (Glucagon/Insulin) Secretion
The University of Texas Health Science Center at San Antonio·interventional·Posted Oct 30, 2015·Updated Sep 17, 2020
In Brief
A Phase 3 clinical trial evaluating Dapagliflozin and Placebo for Type II Diabetes Mellitus. Completed, enrolled 30 participants across 1 site.
Detailed Summary
In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP following SGLT2 inhibition.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType II Diabetes Mellitus
CountriesUnited States
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedOct 2015
Primary CompletionOct 2018
Study CompletionOct 2019
TodayJul 2026
First PostedOct 30, 2015
Enrollment StartOct 23, 2015
Primary CompletionOct 1, 2018
Study CompletionOct 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.7 years ago
Interventions
Dapagliflozindrug
SGLT2 inhibitor (dapagliflozin)
Placebodrug
Placebo Comparator